21 March
2024
4basebio
PLC
("4basebio" or the
"Company")
4basebio announces key
milestone with its client progressing into Phase I clinical trials
of an
mRNA vaccine
manufactured from 4basebio’s
opDNA™
Cambridge, UK, 21 March
2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider
of novel synthetic DNA products and a non-viral, thermostable
nucleic acid delivery platform, today announces that the Company’s
client, Helix Nanotechnologies Inc. (“HelixNano”) has received HREC
approval to progress into a Phase I clinical trial in Australia with HN-0001, an mRNA vaccine
generated from 4basebio’s synthetic DNA, opDNA™.
4basebio will continue to
support HelixNano with the manufacture of GMP synthetic DNA planned
for later in 2024.
Dr Amy Walker, VP of Research and Business
Development at the Company, commented:
"It’s been a pleasure
to work with such an innovative company on their journey to the
clinic and we are delighted to see an mRNA vaccine manufactured
using 4basebio DNA progressing into patients; this represents
another significant milestone for the
company.”
“4basebio has several
clients requiring GMP grade DNA and progressing towards clinical
trials; we are of course very pleased to be supporting our clients
in their clinical programs.”
Dr Marianna Keaveney, Director of Clinical Product
Development at HelixNano, commented:
“It's an incredible
milestone for HelixNano to secure approval for our first clinical
trial, and we would not have been able to develop this drug product
without the commitment of the 4basebio team. We look forward to
continuing our work
together.”
For further enquiries,
please
contact:
|
4basebio
PLC
Heikki Lanckriet
|
+44 (0)12 2396
7943 |
|
Nominated
Adviser
Cairn Financial Advisers
LLP
Jo Tuner / Sandy
Jamieson
|
+44 (0)20 7213
0880 |
|
Broker
Cavendish
Geoff Nash / Charlie
Beeson / Nigel Birks
|
+44 (0)20 7220
0500 |
|
Lionsgate Communications
(Media Enquiries)
Jonathan
Charles
|
+44 (0)77
91892509
|
Notes to
Editors
About
4basebio
4basebio (AIM: 4BB) is an
innovation driven life biotechnology company focused on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high performance synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company’s objective is to become a market leader in the manufacture
and supply of high-quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients. The company is offering GMP compliant DNA
starting materials suitable for use in AAV viral vector production
as well as mRNA vaccine and therapeutics
production.
About Helix
Nanotechnologies Inc.
Helix Nanotechnologies
Inc. is a biotechnology company headquartered in Boston, MA. HelixNano is focused on building a
universal interface to the immune system to tap into the innate
power of the human body to fight disease. HelixNano is currently
developing mRNA-based therapeutics in infectious disease, oncology,
and other
indications.
Forward-looking
statements
This announcement may
contain certain statements about the future outlook for 4basebio.
Although the directors believe their expectations are based
on reasonable assumptions, any statements about future outlook may
be influenced by factors that could cause actual outcomes and
results to be materially different.